Carcinosarcoma of the Ovary: Analysis of 13 Cases and Review of the LiteratureLoizzi V. · Cormio G. · Camporeale A. · Falagario M. · De Mitri P. · Scardigno D. · Putignano G. · Selvaggi L.E.
Department of Gynecology, Obstetrics and Neonatology, Policlinico di Bari, University of Bari, Bari, Italy
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objectives: The aim of this study was to evaluate our experience with patients affected by ovarian carcinosarcoma. Patients and Methods: During a 16-year period, data on 13 patients with ovarian carcinosarcoma were collected. They were obtained from hospital charts and follow-up visits. Survival curves were estimated by the Kaplan-Meier method and compared using the log-rank test. All tests were two-tailed with p values <0.05 considered significant. Results: Our study was conducted on 13 patients with ovarian carcinosarcoma referred to our unit, during an observation time of about 16 years (March 1994 to October 2010). An improved survival was observed in patients treated with optimal cytoreductive surgery with residual tumors <2 cm (30 vs. 5 months; p = 0.042). All patients underwent adjuvant chemotherapy based on the combination of cisplatin, epirubicin and ifosfamide (PEI) and taxol and carboplatin (TAX-CBDCA) regimen. Overall survival of the patient population was 17 months. Conclusions: Similarly to data published in the literature, we observed that malignant mixed mullerian ovarian tumors are very aggressive and are usually diagnosed at an advanced age and at an advanced stage of disease. Therefore, due to the rarity of the tumor we would like to add our series to those already published in the literature, although our treatment recommendations are actually based upon retrospective studies with a small patient population.
© 2011 S. Karger AG, Basel
- Cantrell LA, Van Le L: Carcinosarcoma of the ovary a review. Obstet Gynecol Surv 2009;64:673–680; quiz 697.
Duman BB, et al: Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature. Arch Gynecol Obstet 2011, Epub ahead of print.
- Brown E, et al: Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer 2004;100:2148–2153.
- Mok JE, et al: Malignant mixed mullerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer 2006;16:101–105.
- Leiser AL, et al: Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 2007;105:657–661.
- Barnholtz-Sloan JS, et al: Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT). Gynecol Oncol 2004;93:506–512.
- Rutledge TL, et al: Carcinosarcoma of the ovary-a case series. Gynecol Oncol 2006;100:128–132.
- Rebischung C, et al: Alpha-fetoprotein production by a malignant mixed Mullerian tumor of the ovary. Gynecol Oncol 2000;77:203–205.
- Sood AK, et al: Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Cancer 1998;82:1731–1737.
- Athavale R, et al: The effect of epithelial and stromal tumor components on FIGO stages III and IV ovarian carcinosarcomas treated with primary surgery and chemotherapy. Int J Gynecol Cancer 2007;17:1025–1030.
- Muntz HG, et al: Malignant mixed mullerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy. Cancer 1995;76:1209–1213.
- Barakat RR, et al: Mixed mesodermal tumor of the ovary: analysis of prognostic factors in 31 cases. Obstet Gynecol 1992;80:660–664.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.